Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Bose

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket TrialKomal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
American Journal of Human Genetics|August 13, 2011
Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosaRıza Köksal Ozgül, Anna M Siemiatkowska, Didem Yücel, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.
Breast Cancer Research and Treatment|April 28, 2021
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimensBeverly Moy, Mafalda Oliveira, Cristina Saura, et al.
Nature Methods|October 15, 2013
DGIdb: mining the druggable genomeMalachi Griffith, Obi L Griffith, Adam C Coffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migrationDaniel J Zabransky, Christopher L Yankaskas, Rory L Cochran, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket TrialKomal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
American Journal of Human Genetics|August 13, 2011
Exome sequencing and cis-regulatory mapping identify mutations in MAK, a gene encoding a regulator of ciliary length, as a cause of retinitis pigmentosaRıza Köksal Ozgül, Anna M Siemiatkowska, Didem Yücel, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
Breast (Edinburgh, Scotland)|January 26, 2023
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancerArlene Chan, Manuel Ruiz-Borrego, Gavin Marx, et al.
Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.
Breast Cancer Research and Treatment|April 28, 2021
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimensBeverly Moy, Mafalda Oliveira, Cristina Saura, et al.
Nature Methods|October 15, 2013
DGIdb: mining the druggable genomeMalachi Griffith, Obi L Griffith, Adam C Coffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Genomic Characterization of Primary Invasive Lobular Breast CancerChristine Desmedt, Gabriele Zoppoli, Gunes Gundem, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migrationDaniel J Zabransky, Christopher L Yankaskas, Rory L Cochran, et al.
Pageof 8